Traws Pharma
TRAW
25 hedge funds and large institutions have $11.1M invested in Traws Pharma in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 38 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0.37% more ownership
Funds ownership: 0.04% → 0.41% (+0.37%)
55% less funds holding
Funds holding: 56 → 25 (-31)
67% less capital invested
Capital invested by funds: $33.6M → $11.1M (-$22.5M)
82% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$986K |
| 2 |
Morgan Stanley
New York
|
+$896K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$664K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
+$226K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$3.69M |
| 2 |
Millennium Management
New York
|
-$2.82M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.31M |
| 4 |
Principal Financial Group
Des Moines,
Iowa
|
-$1.26M |
| 5 |
VF
Virtu Financial
New York
|
-$836K |
TRAW Hedge Fund Activity: Q2 2021 in Review
25 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2021, worth a combined $11.1M — down 67% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of TRAW and 7 opened new positions — a net loss of 31 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was State Street, adding an estimated $986K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $3.69M sold.
- 25 institutional investors held Traws Pharma (TRAW) as of Q2 2021, down from 56 in Q1 2021.
- Funds reported $11.1M of Traws Pharma stock for Q2 2021, down 67% quarter-over-quarter.
- 7 funds opened new Traws Pharma positions in Q2 2021 and 38 closed out, a net change of -31 holders.
- The largest Traws Pharma buyer in Q2 2021 was State Street, an estimated $986K added.
- The largest Traws Pharma seller in Q2 2021 was Renaissance Technologies, an estimated $3.69M sold.
Based on aggregated 13F filings for Q2 2021.